Wednesday, 27 February 2013

FDA approves Osphena for postmenopausal women experiencing pain during sex



February 27, 2013, Hyderabad, India –The U.S. Food and Drug Administration today approved Osphena (ospemifene) to treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause.

Dyspareunia is a condition associated with declining levels of estrogen hormones during menopause. Less estrogen can make vaginal tissues thinner, drier and more fragile, resulting in pain during sexual intercourse.

Osphena, a pill taken with food once daily, acts like estrogen on vaginal tissues to make them thicker and less fragile, resulting in a reduction in the amount of pain women experience with sexual intercourse.

“Dyspareunia is among the problems most frequently reported by postmenopausal women,” said Victoria Kusiak, M.D., deputy director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research. “Osphena provides an additional treatment option for women seeking relief.”

Osphena’s safety and effectiveness were established in three clinical studies of 1,889 postmenopausal women with symptoms of vulvar and vaginal atrophy. Women were randomly assigned to receive Osphena or a placebo. After 12 weeks of treatment, results from the first two trials showed a statistically significant improvement of dyspareunia in Osphena-treated women compared with women receiving placebo. Results from the third study support Osphena’s long-term safety in treating dyspareunia.

Osphena is being approved with a boxed warning alerting women and health care professionals that the drug, which acts like estrogen on vaginal tissues, has shown it can stimulate the lining of the uterus (endometrium) and cause it to thicken. In fertile women, this thickening of the endometrium occurs monthly before menstruation. Postmenopausal women no longer experience menstruation, and a stimulated endometrium is not normal. Women should see their health care professional if they experience any unusual bleeding as it may be a sign of endometrial cancer or a condition that can lead to it. Osphena should be prescribed for the shortest duration consistent with treatment goals and risks for the individual woman.

The boxed warning also states the incidence rates of thrombotic and hemorrhagic strokes (0.72 and 1.45 per thousand women, respectively) and the incidence rate of deep vein thrombosis (1.45 per thousand women). These rates are considered to represent low risks in contrast to the increased risks of stroke and deep vein thrombosis seen with estrogen-alone therapy.

Common side effects reported during clinical trials included hot flush/flashes, vaginal discharge, muscle spasms, genital discharge and excessive sweating.


Tuesday, 26 February 2013

FDA approves Stivarga for advanced gastrointestinal stromal tumors



 
February 26, 2013, Hyderabad, India – The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and no longer respond to other FDA-approved treatments for this disease.

GIST is a tumor in which cancerous cells form in the tissues of the gastrointestinal tract, part of the body’s digestive system. According to the National Cancer Institute, an estimated 3,300 to 6,000 new cases of GIST occur yearly in the United States, most often in older adults.

Stivarga, a multi-kinase inhibitor, blocks several enzymes that promote cancer growth. With this new approval, Stivarga is intended to be used in patients whose GIST cancer cannot be removed by surgery or has spread to other parts of the body (metastatic) and is no longer responding to Gleevec (imatinib) and Sutent (sunitinib), two other FDA-approved drugs to treat GIST.

“Stivarga is the third drug approved by the FDA to treat gastrointestinal stromal tumors,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “It provides an important new treatment option for patients with GIST in which other approved drugs are no longer effective.”

Stivarga was reviewed under the FDA’s priority review program, which provides an expedited six-month review for drugs that may provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products. The drug was also granted orphan product designation because it is intended to treat a rare disease.

The safety and effectiveness of Stivarga for this use were evaluated in a clinical study of 199 patients with GIST that could not be surgically removed and progressed after treatment with Gleevec or Sutent. Patients were randomly assigned to receive either Stivarga or a placebo. All patients also received optimal supportive care, which includes treatments to help manage side effects and symptoms of cancer.

Patients in the study took Stivarga or placebo until either the cancer progressed or the side effects became unacceptable. Results showed patients who took Stivarga had a delay in tumor growth (progression-free survival) that was, on average, 3.9 months later than patients who were given placebo. Patients who received the placebo were given the opportunity to switch to Stivarga when their cancer progressed.

The most common side effects reported in patients treated with Stivarga were weakness and fatigue, hand-foot syndrome (also called palmar-plantar erythrodysesthesia), diarrhea, loss of appetite, high blood pressure, mouth sores, infection, changes in voice volume or quality, pain, weight loss, stomach pain, rash, fever and nausea.

Serious side effects, which occurred in less than one percent of patients, were liver damage, severe bleeding, blistering and peeling of skin, very high blood pressures requiring emergency treatment, heart attacks and perforations (holes) in the intestines.

Stivarga was approved in September 2012 to treat colorectal cancer.

Russian Helicopters showcases unique archive photos of Kamov and Mil bureauxat photo exhibition to mark 90 years of Russian civil aviation



 
Moscow / 26 February 2013– Russian Helicopters, part of state defence holding Oboronprom and a leading global designer and manufacturer of helicopters, has put unique archive photographs on show at an exhibition being held in Terminal F of Moscow’s Sheremetyevo International Airport to celebrate 90 years of civil aviation in Russia.

Russia marked the 90th anniversary of civil aviation in the country on 9 February 2013. The exhibition, entitled “Russian Civil Aviation – 90 Years in the Skies and on the Ground”, honours this anniversary for the country’s aeronautics, and the pictures capture the civil helicopters and aircraft that have created the history of passenger and goods transportation in Russia. The display is a unique photo documentary reflecting aerospace from the 1930s to the present day, from the first developments to the latest machines.

Helicopter manufacturing has written its own chapter in the history of Russian civil aviation. The list of great aerospace constructors would not be complete without Mikhail Mil and Nikolai Kamov, the brilliant helicopter-builders who laid the foundations for the sector that grew and strengthened through the 1950s and 1960s. The names Mil and Kamov are known around the world, and have become a genuine Russian brand.

The exhibition at Sheremetyevo includes photographs from the archives of the renowned Mil and Kamov bureaux. The pictures on display are not staged shots, but rather a daily chronicle reflecting the real lives of those who created and operated the helicopters.

The pictures show Nikolai Kamov discussing with colleagues the workload of the Ka-18, which in 1958 received a gold medal at the World’s Fair in Brussels. Then there is the super-heavy and experienced Mi-12, which set a world record that still stands today by lifting 40 tons of cargo to a height of 2,000 meters. Another record-holder is the Ka-26, which has set five world marks. In other pictures there is miniature V-7 – the only rotorcraft in the world with turbojet engines at the ends of the blades. And of course there is a portrait of the country’s first transport helicopter – the Mi-4 – at work, landing on the roof of a building in Moscow. Passenger, medical and agricultural versions of the Mi-4 were produced in addition to the transport model, with 3,852 manufactured in total.

Helicopters are indispensable in civil aviation due to their agility, their ability to land on rough ground, and their economical fuel consumption. For many civilian operations, helicopters’ ability to take off and land vertically represents a major advantage over aircraft. “Russia is designed for helicopters,” Mikhail Mil said. Helicopters fly a wide range of transportation missions, helping oil workers and other professionals in their daily work in remote places where the ground is inaccessible by air. Helicopters help to save people, to fight fires and deal with natural disasters.

Russia has a proud tradition and a long history of helicopter manufacturing. The country’s designers created a design for civil aircraft, many of which are still unique, unmatched anywhere in the world. Russian Helicopters is certain that the unique pictures on show at the exhibition at Sheremetyevo will help strengthen the image of the Russian helicopter industry to the widest possible audience.

Russian Helicopters continues to build on the traditions established by the great designers of the past. Today the company supplies multi-role helicopters to major global and Russian operators of civil helicopters and numerous government bodies. Russian helicopters continue to serve society to the benefit of the whole planet. 





Russian Helicopters will showcase Ka-32A11BC in Australia




Moscow / 26 February 2013 – Russian Helicopters, part of state defence holding Oboronprom – the part of Russian Technologies (Rostec) State Corporation and a leading global designer and manufacturer of helicopters, will bring its Australian calling card – the medium multi-role Ka-32A11BC – to Avalon 2013, the international aviation exhibition taking place from 26 February to 3 March in Geelong. The Russian Helicopters display can be found at stand 2F4.
Though Australia is a new market for Russian Helicopters, the company’s helicopters are in high demand across the Asia-Pacific region. More than 1,200 Russian-built helicopters already operate in one of the fastest-growing regions of the planet, and demand for reliable and economical helicopters is continuing to grow along with the regional economy.

The Ka-32A11BC received its Australian certificate of airworthiness in December 2012, allowing Australian operators to use the helicopter for fire-fighting, search-and-rescue operations, goods transport on an external sling and in construction work.

Australia is a country that suffers damage from wildfires every year, and therefore has a need for specialised fire-fighting equipment able to combat the threat. As a fire-fighting helicopter, the Ka-32A11BCcan be equipped with Bambi Buckets and water cannon, which combined with the helicopter’s unique coaxial main rotor system makes the Ka-32A11BCone of the best fire-fighting helicopters in the world.

Russian Helicopters in early 2013 launched the Global Helicoptor Firefighting,Initiative to further the development of helicopter fire-fighting equipment. The Initiative aims to make the use of specialised fire-fighting helicopters more effective, and will involve sector specialists and other relevant companies from around the world. The goal of the programme is to combat the threat of natural and manmade fires on a global level. The Ka-32A11BC has been chosen as the symbol of the GHFI.

Alongside a growing market for corporate helicopter transportation, demand for multi-role transport helicopters is also increasing. Australian operators will be shown the new medium multi-role Ka-62, which uses the latest composite materials in its construction. The Ka-62 is a single-rotor design, with an enclosed multi-bladed tail rotor. It is powered by twin Turbomeca Ardiden 3G engines that generate 1,680 HP. Experts say that the Ka-62 will become a bestseller for Russian Helicopters.

Australian helicopter operators will also have the opportunity to see the Mi-8/17 series, the world’s most popular helicopter. Of particular interest will be the latest model in the series, the Mi-171A2, which combines the finest qualities of its predecessors – reliability, simplicity of use and versatility – with the advantages of the latest helicopter construction technologies. The Mi-171A2 is destined to become one of the most efficient and economical helicopters in its class.
Held since 1988, Avalon is the largest air-show in the region. Aviation companies from around the world showcase their equipment, alongside the Australian Air Force, Navy and the US Air Force.